Natalie Galant, PhD

Co-Founder and CEO 

Dr. Natalie Galant is the CEO and co-founder of Paradox Immunotherapeutics, a pharmaceutical company dedicated to the creation of antibody therapies for the treatment of rare protein misfolding diseases, especially those characterized by amyloidosis, using a platform with a proven track record of success. Prior to this role, Natalie received her PhD from the University of Toronto’s Department of Medical Biophysics, where her PhD work helped lead to the development of a monoclonal antibody currently in FDA clinical trials for the treatment of cardiac amyloidosis. She is the recipient of numerous academic fellowships, awards (incl. winner of BIO 2023 Start-Up Stadium), and has co-authored several scientific publications in research areas ranging from chemical informatics to immunotherapy drug development.